| Literature DB >> 28838768 |
Sebastião Cézar Radominski1, Wanderley Bernardo2, Ana Patrícia de Paula3, Ben-Hur Albergaria4, Caio Moreira5, Cesar Eduardo Fernandes6, Charlles H M Castro7, Cristiano Augusto de Freitas Zerbini8, Diogo S Domiciano9, Laura M C Mendonça10, Luciano de Melo Pompei6, Mailze Campos Bezerra11, Marco Antônio R Loures12, Maria Celeste Osório Wender13, Marise Lazaretti-Castro7, Rosa M R Pereira9, Sergio Setsuo Maeda7, Vera Lúcia Szejnfeld7, Victoria Z C Borba14.
Abstract
Osteoporosis is the leading cause of fractures in the population older than 50 years. This silent disease affects primarily postmenopausal women and the elderly, and the morbidity and mortality rates are high. The main goal of treating osteoporosis is the prevention of fractures. The identification of populations at risk through early diagnosis and treatment is essential. The last Brazilian guideline for the treatment of postmenopausal osteoporosis was elaborated in 2002. Since then, new strategies for diagnosis and risk stratification have been developed, and drugs with novel action mechanisms have been added to the therapeutic arsenal. The Osteoporosis and Osteometabolic Diseases Committee of the Brazilian Society of Rheumatology, in conjunction with the Brazilian Medical Association and other Societies, has developed this update of the guidelines for the treatment of postmenopausal osteoporosis according to the best scientific evidence available. This update is intended for professionals in many medical and health specialties involved in the treatment of osteoporosis, for physicians in general and for health-related organizations.Entities:
Keywords: Diagnosis; Diagnóstico; Diretrizes; Guidelines; Menopausa; Menopause; Mulher; Osteoporose; Osteoporosis; Terapia; Therapy; Woman
Mesh：
Substances：
Year: 2017 PMID： 28838768 DOI： 10.1016/j.rbre.2017.07.001
Source DB: PubMed Journal: Rev Bras Reumatol Engl Ed ISSN： 2255-5021